<DOC>
	<DOCNO>NCT01143909</DOCNO>
	<brief_summary>With aim restrict inappropriate fresh frozen plasma ( FFP ) transfusion critically ill patient , randomize clinical trial conduct subgroup intensive care ( ICU ) patient undergo invasive procedure . The objective ass effectiveness cost omit prophylactic FFP transfusion compare current practice prophylactic transfusion , non-bleeding ICU patient coagulopathy .</brief_summary>
	<brief_title>Transfusion Fresh Frozen Plasma Non-bleeding Intensive Care Unit ( ICU ) Patients</brief_title>
	<detailed_description>Rationale : Fresh frozen plasma ( FFP ) effective therapy correct deficiency multiple coagulation factor bleed . In past year , use FFP increase , particular patient Intensive Care Unit ( ICU ) , expand include prophylactic use patient coagulopathy prior undergo invasive procedure . Retrospective study suggest prophylactic use FFP prevent bleeding , carry risk transfusion-related morbidity . However , 50 % FFP administer non-bleeding ICU patient . Objective : With aim restrict inappropriate FFP transfusion critically ill patient , randomize clinical trial conduct subgroup ICU patient coagulopathy undergoing invasive procedure . The objective ass effectiveness cost prophylactic FFP transfusion ( current practice ) compare prophylactic transfusion , non-bleeding ICU patient coagulopathy , prior undergo invasive procedure ( e.g . placement central venous catheter , tracheostomy , chest tube ) . Study design : Prospective , multicentre , randomize , open-label , blinded end point evaluation ( PROBE ) design .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>18 year old INR &gt; 1.5 &lt; 3.0 undergoing invasive procedure ( insertion central venous catheter , chest drain , percutaneous tracheostomy ) clinically overt bleeding time procedure ( excludes minor epistaxis , minor gum bleeding , microscopic hematuria , superficial bruise , normal menses ) thrombocytopenia &lt; 30 x 109/L . use abciximab , tirofiban , ticlopidine activate protein C use heparin &lt; 1 hour prior procedure , low molecular weight heparin therapeutic dos &lt; 12 hour prior procedure history congenital acquire coagulation factor deficiency bleed diathesis inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Fresh frozen plasma</keyword>
	<keyword>Coagulopathy</keyword>
	<keyword>Intensive care</keyword>
	<keyword>Adverse effect</keyword>
	<keyword>Lung injury</keyword>
</DOC>